NASDAQ: TSHA

Taysha Gene Therapies Inc Stock Forecast, Predictions & Price Target

The consensus among 6 Wall Street analysts covering (NASDAQ: TSHA) stock is to Strong Buy TSHA stock.

Out of 6 analysts, 4 (66.67%) are recommending TSHA as a Strong Buy, 2 (33.33%) are recommending TSHA as a Buy, 0 (0%) are recommending TSHA as a Hold, 0 (0%) are recommending TSHA as a Sell, and 0 (0%) are recommending TSHA as a Strong Sell.

If you're new to stock investing, here's how to buy Taysha Gene Therapies stock.

(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of -31.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Taysha Gene Therapies's revenue in 2024 is $15,451,000.On average, 2 Wall Street analysts forecast TSHA's revenue for 2024 to be $2,777,221,384, with the lowest TSHA revenue forecast at $2,244,219,300, and the highest TSHA revenue forecast at $3,310,223,468. On average, 2 Wall Street analysts forecast TSHA's revenue for 2025 to be $1,870,182,750, with the lowest TSHA revenue forecast at $1,496,146,200, and the highest TSHA revenue forecast at $2,244,219,300.

In 2026, TSHA is forecast to generate $935,091,375 in revenue, with the lowest revenue forecast at $935,091,375 and the highest revenue forecast at $935,091,375.

According to 6 Wall Street analysts that have issued a 1 year TSHA price target, the average TSHA price target is $7.00, with the highest TSHA stock price forecast at $9.00 and the lowest TSHA stock price forecast at $5.00.

On average, Wall Street analysts predict that Taysha Gene Therapies's share price could reach $7.00 by Apr 19, 2025. The average Taysha Gene Therapies stock price prediction forecasts a potential upside of 204.35% from the current TSHA share price of $2.30.

(NASDAQ: TSHA) forecast ROE is N/A, which is considered weak.